Haemonetics Corporation Cash Flow Conversion Efficiency
Haemonetics Corporation cash flow conversion efficiency. Based on the latest financial reports, Haemonetics Corporation (HAE) has a cash flow conversion efficiency ratio of 0.089x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($70.94 Million) by net assets ($796.32 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Haemonetics Corporation (1992–2026)
Cash flow conversion efficiency of Haemonetics Corporation from 1992 to 2026. This chart illustrates how Haemonetics Corporation's cash flow conversion efficiency has evolved over time, based on yearly financial data. View HAE live share price for real-time trading data and today's change.
Haemonetics Corporation Cash Flow Conversion Ratio Explained
Haemonetics Corporation cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Haemonetics Corporation Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Haemonetics Corporation ranked by their cash flow conversion efficiency. Also see Haemonetics Corporation stock valuation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tongding Interconnection Information
SHE:002491
|
-0.002x |
|
Adaptive Biotechnologies Corp
NASDAQ:ADPT
|
-0.032x |
|
KANSAI PAINT SPON.ADR/1/2
F:KAP0
|
N/A |
|
China Baoan Group Co Ltd
SHE:000009
|
0.010x |
|
Multiplan Empreendimentos Imobiliários S.A
SA:MULT3
|
0.036x |
|
Metro Brands Limited
NSE:METROBRAND
|
0.069x |
|
Legend Holdings Corporation
F:1PC
|
-0.009x |
|
IIFL Finance Limited
NSE:IIFL
|
-0.295x |
Annual Cash Flow Conversion Efficiency for Haemonetics Corporation (1992–2026)
The table below shows the annual cash flow conversion efficiency of Haemonetics Corporation from 1992 to 2026. Review HAE free cash flow to operating cash ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2026-03-31 | $893.76 Million | $293.22 Million | 0.328x | +48.19% |
| 2025-03-31 | $820.84 Million | $181.72 Million | 0.221x | +16.93% |
| 2024-03-31 | $959.96 Million | $181.75 Million | 0.189x | -43.28% |
| 2023-03-31 | $818.00 Million | $273.06 Million | 0.334x | +45.22% |
| 2022-03-31 | $749.42 Million | $172.26 Million | 0.230x | +54.57% |
| 2021-03-31 | $731.67 Million | $108.81 Million | 0.149x | -44.82% |
| 2020-03-31 | $587.11 Million | $158.22 Million | 0.269x | +13.00% |
| 2019-03-31 | $667.87 Million | $159.28 Million | 0.238x | -18.56% |
| 2018-03-31 | $752.43 Million | $220.35 Million | 0.293x | +35.59% |
| 2017-03-31 | $739.61 Million | $159.74 Million | 0.216x | +27.60% |
| 2016-03-31 | $719.98 Million | $121.86 Million | 0.169x | +9.95% |
| 2015-03-31 | $826.12 Million | $127.18 Million | 0.154x | -7.36% |
| 2014-03-31 | $839.61 Million | $139.52 Million | 0.166x | +50.25% |
| 2013-03-31 | $769.18 Million | $85.07 Million | 0.111x | -29.50% |
| 2012-03-31 | $735.08 Million | $115.32 Million | 0.157x | -12.81% |
| 2011-03-31 | $686.14 Million | $123.45 Million | 0.180x | -18.33% |
| 2010-03-31 | $593.12 Million | $130.67 Million | 0.220x | +2.21% |
| 2009-03-31 | $539.88 Million | $116.36 Million | 0.216x | +37.14% |
| 2008-03-31 | $494.19 Million | $77.67 Million | 0.157x | -9.79% |
| 2007-03-31 | $479.65 Million | $83.56 Million | 0.174x | -10.13% |
| 2006-03-31 | $441.65 Million | $85.62 Million | 0.194x | -3.32% |
| 2005-03-31 | $355.13 Million | $71.21 Million | 0.201x | -24.82% |
| 2004-03-31 | $279.75 Million | $74.61 Million | 0.267x | +36.35% |
| 2003-03-31 | $223.24 Million | $43.67 Million | 0.196x | +43.70% |
| 2002-03-31 | $236.82 Million | $32.24 Million | 0.136x | -51.91% |
| 2001-03-31 | $215.52 Million | $61.01 Million | 0.283x | +9.31% |
| 2000-03-31 | $206.44 Million | $53.47 Million | 0.259x | +70.53% |
| 1999-03-31 | $221.90 Million | $33.70 Million | 0.152x | +44.95% |
| 1998-03-31 | $194.70 Million | $20.40 Million | 0.105x | -11.59% |
| 1997-03-31 | $225.30 Million | $26.70 Million | 0.119x | -53.07% |
| 1996-03-31 | $217.00 Million | $54.80 Million | 0.253x | +212.75% |
| 1995-03-31 | $193.20 Million | $15.60 Million | 0.081x | -51.91% |
| 1994-03-31 | $160.80 Million | $27.00 Million | 0.168x | -40.74% |
| 1993-03-31 | $126.70 Million | $35.90 Million | 0.283x | +36.55% |
| 1992-03-31 | $90.60 Million | $18.80 Million | 0.208x | -- |
About Haemonetics Corporation
Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information tech… Read more